Article

Transcatheter Aortic Valve Implantation for Stenosed and Regurgitant Aortic Valve Bioprostheses CoreValve for Failed Bioprosthetic Aortic Valve Replacements

Sussex Cardiac Centre, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK.
Journal of the American College of Cardiology (Impact Factor: 15.34). 01/2010; 55(2):97-101. DOI: 10.1016/j.jacc.2009.06.060
Source: PubMed

ABSTRACT Transcatheter aortic valve implantation is increasingly being used to treat severe aortic stenosis in patients with high operative risk. In an aging population the incidence of aortic stenosis is rising, and increasing numbers of elderly patients are undergoing aortic valve replacement with bioprosthetic valves. Therefore, there is a corresponding increase in prosthetic degeneration. This presents cardiologists with a cohort of patients for whom the risk of re-do aortic valve surgery is prohibitive. We present the first series of such patients with degenerative bioprosthetic stenosis or regurgitation successfully treated with CoreValve (Medtronic, Luxembourg) implantation.

Download full-text

Full-text

Available from: David Hildick-Smith, Aug 14, 2015
0 Followers
 · 
110 Views
  • Source
    • "The Edwards SAPIEN valve may be better suited to VIV implantation (Kempfert et al., 2010), although the Medtronic CoreValve system has been successfully used (Khawaja et al., 2010). There are promising early results for VIV, although reports tend to be anecdotal or restricted to small case series, and no large comparative studies are currently available (Ferrari et al., 2010; Kempfert et al., 2010; Khawaja et al., 2010; Olsen et al., 2010; Sharp et al., 2010). Transvalvular gradients post-procedure are usually satisfactory (Ferrari et al., 2010; Kempfert et al., 2010; Walther et al., 2008a), while residual aortic regurgitation tends to be minimal (Kempfert et al., 2010). "
    Aortic Valve, 12/2011; , ISBN: 978-953-307-561-7
  • [Show abstract] [Hide abstract]
    ABSTRACT: Spectral efficiency is the most important aspect in wireless communication systems and cellular mobile radio. As speech transmissions are the most used form of communications in the personal communication systems, the low bit speech codecs play an important role in determining the system's spectral efficiency. A toll quality low bit rate speech codec that was proposed to meet the personal communication system's requirement is the CS-ACELP speech codec. The speech codec has high robustness to withstand high-bit error rates and performs well in tandeming conditions, hence leading to efficient bandwidth utilization and increased channel capacity. In this paper several optimization techniques are presented for efficient implementation of ITU G.729 standard (CS-ACELP, conjugate structure algebraic code excited linear prediction) of 8 Kbit/s bit rate on a real time digital signal processor (DSP), with the aim of overcoming the limitation of computational burden and also scaling this application for enhanced speed to process more channels. These techniques are in general applicable to any speech codec and DSP processor platform.
    Vehicular Technology Conference, 2004. VTC2004-Fall. 2004 IEEE 60th; 10/2004
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aortic stenosis affects a significant number of patients worldwide, and carries a dismal prognosis once symptoms develop. Unfortunately, a large number of patients present a prohibitive risk for surgical aortic valve replacement. Therefore, transcatheter aortic valve implantation has emerged as a promising technology for providing treatment to this group of patients. Currently available valves include the balloon-expandable Edwards SAPIEN valve (Edwards Lifesciences, Irvine, CA), which is usually implanted via a transfemoral or transapical approach, and the self-expanding CoreValve ReValving system (Medtronic, Minneapolis, MN), which uses only the transfemoral route. Early experience with the procedure performed on a compassionate-use basis was encouraging, and led to a number of first-in-man and feasibility studies. These trials demonstrated the safety and efficacy of valve implantation and led to CE (European Conformity) mark approval of both valves in Europe. Use of the SAPIEN valve in the United States is limited to the recently completed PARTNER (Placement of Aortic Transcatheter Valve) randomized trial comparing transcatheter and surgical aortic valve replacement in high-risk patients, and its post-trial registry. The CoreValve is not yet available in the United States. With improved device technology, better understanding of patient selection and pre- and periprocedural imaging, and greater procedural experience, widespread diffusion of transcatheter aortic valve implantation is expected.
    Current Cardiology Reports 09/2010; 12(5):393-403. DOI:10.1007/s11886-010-0126-5
Show more